Empowering Precision Diagnostics
Bringing ImmunoGuide ELISA technologies to Europe and beyond
Validated ELISA kits for therapeutic drug monitoring and anti-drug antibody detection, for clinical labs, research institutions, and biotech teams. For Research Use Only.
Featured ELISA kits
Drug-level and anti-drug antibody assays across TNF-alpha, VEGF, EGFR, HER2, and more.
ADALIMUMAB ELISA
Analyte: Adalimumab
View kitADALIMUMAB ELISA (MAB-BASED)
Analyte: Adalimumab
View kitAFLIBERCEPT ELISA
Analyte: Aflibercept
View kitANTIBODY TO ADALIMUMAB ELISA
Analyte: Adalimumab
View kitANTIBODY TO BEVACIZUMAB ELISA
Analyte: Bevacizumab
View kitANTIBODY TO CERTOLIZUMAB PEGOL ELISA
Analyte: Certolizumab Pegol
View kitFrom our journal
Background on ELISA methods, therapeutic drug monitoring, anti-drug antibodies, and assay validation.
What "Highly Similar" Actually Requires: Analytical Methods for mAb Biosimilar Characterization
Regulatory approval of mAb biosimilars now depends less on replicating clinical trial results and more on high-resolution analytical characterization. A 2026 BioDrugs review of successful US and EU dossiers maps the assay strategies that matter, while the FDA's September 2025 waiver of a clinical efficacy study for a ustekinumab biosimilar makes the principle concrete for immunoassay and TDM scientists.
Measuring the Pathogen, Not the Host: A High-Sensitivity ESAT-6 Blood Assay Distinguishes Active TB Across the Infection Spectrum
A high-sensitivity biosensor for circulating ESAT-6 protein, a direct secretory product of Mycobacterium tuberculosis, produced a stepwise quantitative signal across the full TB infection spectrum in a 217-patient cohort presented at ADLM 2026. Unlike IGRAs, which measure host immune response, this antigen-direct approach distinguished active disease from latent infection and uninfected contacts with an AUC of 0.976, as reported in conference coverage pending peer-reviewed publication. Full analytical validation and prospective clinical data remain outstanding.
ADA Assay Design for Denosumab Biosimilars: The sRANKL Interference Problem and How to Solve It
Standard acid dissociation pretreatment in denosumab anti-drug antibody bridging assays can generate false-positive ADA rates approaching 96 to 98%, driven by soluble RANKL accumulation after dosing. Adding osteoprotegerin as a specificity tier corrects observed false-positive incidence to 3.9% or below. This article reviews the assay mitigation strategy alongside the clinical immunogenicity evidence from ten FDA-approved denosumab biosimilar programs.